Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 190 articles: HTML format

Single Articles

April 2024
1. DAI W, Wang Y, Liao J, Wei X, et al
   Electronic Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized, Controlled Trial.
   J Clin Oncol. 2024 Apr 4:JCO2301854. doi: 10.1200/JCO.23.01854.
   PubMed     Abstract available
   
   
   March 2024
2. NEAL J, Pavlakis N, Kim SW, Goto Y, et al
   CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
   J Clin Oncol. 2024 Mar 29:JCO2302166. doi: 10.1200/JCO.23.02166.
   PubMed     Abstract available
   
   
   
3. POTTER AL, Xu NN, Senthil P, Srinivasan D, et al
   Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
   J Clin Oncol. 2024 Mar 27:JCO2301780. doi: 10.1200/JCO.23.01780.
   PubMed     Abstract available
   
   
   
4. KATHURIA H, Wiener RS
   Toward Racial Equity in Lung Cancer Screening Eligibility.
   J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351.
   PubMed    
   
   
   
5. RODRIGUEZ GM, Popat R, Rosas LG, Patel MI, et al
   Racial and Ethnic Disparities in Intensity of Care at the End of Life for Patients With Lung Cancer: A 13-Year Population-Based Study.
   J Clin Oncol. 2024 Mar 13:JCO2301045. doi: 10.1200/JCO.23.01045.
   PubMed     Abstract available
   
   
   February 2024
6. HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al
   Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
   J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339.
   PubMed    
   
   
   
7. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
   Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
   J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746.
   PubMed     Abstract available
   
   
   
8. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
   Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
   J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744.
   PubMed     Abstract available
   
   
   
9. PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al
   Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
   J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417.
   PubMed     Abstract available
   
   
   
10. REMON J, Besse B, Aix SP, Callejo A, et al
    Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Feb 7:JCO2301521. doi: 10.1200/JCO.23.01521.
    PubMed     Abstract available
    
    
    January 2024
11. MOK T, Nakagawa K, Park K, Ohe Y, et al
    Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    J Clin Oncol. 2024 Jan 22:JCO2301017. doi: 10.1200/JCO.23.01017.
    PubMed     Abstract available
    
    
    
12. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
    Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
    PubMed     Abstract available
    
    
    
13. RICCIUTI B, Lamberti G, Puchala SR, Mahadevan NR, et al
    Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 11:JCO2300580. doi: 10.1200/JCO.23.00580.
    PubMed     Abstract available
    
    
    
14. FENG YN, Xiao L, Xie GY
    Atezolizumab in Advanced Squamous Cell Carcinoma of the Penis.
    J Clin Oncol. 2024;42:242-243.
    PubMed    
    
    
    
15. MERIC-BERNSTAM F, Makker V, Oaknin A, Oh DY, et al
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    J Clin Oncol. 2024;42:47-58.
    PubMed     Abstract available
    
    
    December 2023
16. 
    Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2023 Dec 19:JCO2302574. doi: 10.1200/JCO.23.02574.
    PubMed    
    
    
    
17. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    PubMed    
    
    
    
18. LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations.
    J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876.
    PubMed    
    
    
    
19. 
    Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2302518. doi: 10.1200/JCO.23.02518.
    PubMed    
    
    
    
20. JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al
    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219.
    PubMed     Abstract available
    
    
    
21. TAN DSW, Felip E, de Castro G, Solomon BJ, et al
    Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
    J Clin Oncol. 2023 Dec 1:JCO2300980. doi: 10.1200/JCO.23.00980.
    PubMed     Abstract available
    
    
    November 2023
22. UPRETY D, Remon J, Peters S
    First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
    J Clin Oncol. 2023 Nov 30:JCO2301524. doi: 10.1200/JCO.23.01524.
    PubMed    
    
    
    
23. OHRI N, Jolly S, Cooper BT, Kabarriti R, et al
    Selective Personalized Radioimmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial.
    J Clin Oncol. 2023 Nov 21:JCO2300627. doi: 10.1200/JCO.23.00627.
    PubMed     Abstract available
    
    
    
24. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    PubMed     Abstract available
    
    
    
25. MONK BJ, Colombo N, Tewari KS, Dubot C, et al
    First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
    J Clin Oncol. 2023 Nov 1:JCO2300914. doi: 10.1200/JCO.23.00914.
    PubMed     Abstract available
    
    
    October 2023
26. PARK S, Kim TM, Han JY, Lee GW, et al
    A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04).
    J Clin Oncol. 2023 Oct 20:101200JCO2301891. doi: 10.1200/JCO.23.01891.
    PubMed     Abstract available
    
    
    
27. HENDRIKS LEL, Remon J
    Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Oct 12:JCO2301830. doi: 10.1200/JCO.23.01830.
    PubMed    
    
    
    
28. KHURSHID H, Ismaila N, Bian J, Dabney R, et al
    Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
    J Clin Oncol. 2023 Oct 11:JCO2301435. doi: 10.1200/JCO.23.01435.
    PubMed     Abstract available
    
    
    
29. GARON EB, Lu S, Goto Y, De Marchi P, et al
    Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
    J Clin Oncol. 2023 Oct 3:JCO2300910. doi: 10.1200/JCO.23.00910.
    PubMed     Abstract available
    
    
    September 2023
30. 
    Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
    J Clin Oncol. 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849.
    PubMed    
    
    
    
31. GOTO K, Goto Y, Kubo T, Ninomiya K, et al
    Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2023 Sep 11:JCO2301361. doi: 10.1200/JCO.23.01361.
    PubMed     Abstract available
    
    
    
32. HOE HJ, Solomon BJ
    Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better.
    J Clin Oncol. 2023 Sep 11:JCO2301768. doi: 10.1200/JCO.23.01768.
    PubMed    
    
    
    
33. YU HA, Goto Y, Hayashi H, Felip E, et al
    HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
    J Clin Oncol. 2023 Sep 10:JCO2301476. doi: 10.1200/JCO.23.01476.
    PubMed     Abstract available
    
    
    
34. KENMOTSU H, Yamamoto N, Misumi T, Yoh K, et al
    Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Sep 1:JCO2300179. doi: 10.1200/JCO.23.00179.
    PubMed     Abstract available
    
    
    
35. BEKAII-SAAB TS, Yaeger R, Spira AI, Pelster MS, et al
    Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation.
    J Clin Oncol. 2023;41:4097-4106.
    PubMed     Abstract available
    
    
    August 2023
36. VERGOTE I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, et al
    Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    J Clin Oncol. 2023 Aug 31:JCO2300720. doi: 10.1200/JCO.23.00720.
    PubMed     Abstract available
    
    
    
37. LU BY, Goldberg SB
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Aug 21:JCO2301323. doi: 10.1200/JCO.23.01323.
    PubMed    
    
    
    
38. NADAL E, Rodriguez-Abreu D, Simo M, Massuti B, et al
    Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
    J Clin Oncol. 2023 Aug 21:JCO2202561. doi: 10.1200/JCO.22.02561.
    PubMed     Abstract available
    
    
    
39. OXNARD GR, Chen R, Pharr JC, Koeller DR, et al
    Germline EGFR mutations and familial lung cancer.
    J Clin Oncol. 2023 Aug 14:101200JCO2301372. doi: 10.1200/JCO.23.01372.
    PubMed     Abstract available
    
    
    
40. WU JT, Wakelee HA, Han SS
    Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers.
    J Clin Oncol. 2023 Aug 4:JCO2301060. doi: 10.1200/JCO.23.01060.
    PubMed     Abstract available
    
    
    
41. FARJAH F
    Tradeoffs of Proceeding to Resection Rather Than Mediastinoscopy After Negative Endosonography.
    J Clin Oncol. 2023;41:3782-3784.
    PubMed    
    
    
    July 2023
42. AGGARWAL C, Liu SV
    Zipalertinib in EGFR Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting.
    J Clin Oncol. 2023 Jul 24:JCO2300958. doi: 10.1200/JCO.23.00958.
    PubMed    
    
    
    
43. SINGH N, Daly ME, Ismaila N
    Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Jul 20:JCO2301261. doi: 10.1200/JCO.23.01261.
    PubMed     Abstract available
    
    
    
44. OWEN DH, Singh N, Ismaila N, Masters G, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2.
    J Clin Oncol. 2023 Jul 11:JCO2301055. doi: 10.1200/JCO.23.01055.
    PubMed     Abstract available
    
    
    
45. SIVA S, Sakyanun P, Mai T, Wong W, et al
    Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases.
    J Clin Oncol. 2023;41:3493-3498.
    PubMed     Abstract available
    
    
    June 2023
46. PIOTROWSKA Z, Tan DS, Smit EF, Spira AI, et al
    Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
    J Clin Oncol. 2023 Jun 29:JCO2300152. doi: 10.1200/JCO.23.00152.
    PubMed     Abstract available
    
    
    
47. CHO BC, Ahn MJ, Kang JH, Soo RA, et al
    Lazertinib Versus Gefitinib as First-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results From LASER301.
    J Clin Oncol. 2023 Jun 28:101200JCO2300515. doi: 10.1200/JCO.23.00515.
    PubMed     Abstract available
    
    
    
48. IRAJIZAD E, Fahrmann JF, Marsh T, Vykoukal J, et al
    Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
    J Clin Oncol. 2023 Jun 28:JCO2202424. doi: 10.1200/JCO.22.02424.
    PubMed     Abstract available
    
    
    
49. BESTVINA CM, Garassino MC, Neal JW, Wakelee HA, et al
    Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.
    J Clin Oncol. 2023 Jun 23:JCO2300258. doi: 10.1200/JCO.23.00258.
    PubMed    
    
    
    
50. NEGRAO MV, Spira AI, Heist RS, Janne PA, et al
    Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
    J Clin Oncol. 2023 Jun 16:JCO2300046. doi: 10.1200/JCO.23.00046.
    PubMed     Abstract available
    
    
    
51. SHIMIZU T, Sands J, Yoh K, Spira A, et al
    First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
    J Clin Oncol. 2023 Jun 16:JCO2300059. doi: 10.1200/JCO.23.00059.
    PubMed     Abstract available
    
    
    
52. GOULART BHL, Larkins E, Beaver JA, Singh H, et al
    Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.
    J Clin Oncol. 2023 Jun 8:JCO2300154. doi: 10.1200/JCO.23.00154.
    PubMed    
    
    
    
53. RIELY GJ, Smit EF, Ahn MJ, Felip E, et al
    Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 4:JCO2300774. doi: 10.1200/JCO.23.00774.
    PubMed     Abstract available
    
    
    
54. STINCHCOMBE TE
    Encorafenib and Binimetinib: A New Treatment Option for BRAF(V600E)-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 4:JCO2300983. doi: 10.1200/JCO.23.00983.
    PubMed    
    
    
    
55. KEHL KL, Jaklitsch MT
    Quality Surgical Care and Outcomes for Patients With Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 2:JCO2300745. doi: 10.1200/JCO.23.00745.
    PubMed    
    
    
    
56. DUNNE EG, Fick CN, Jones DR
    Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy.
    J Clin Oncol. 2023 Jun 2:JCO2300867. doi: 10.1200/JCO.23.00867.
    PubMed     Abstract available
    
    
    
57. RAY MA, Akinbobola O, Fehnel C, Saulsberry A, et al
    Surgeon Quality and Patient Survival After Resection for Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 2:JCO2201971. doi: 10.1200/JCO.22.01971.
    PubMed     Abstract available
    
    
    
58. LURAIN K
    Treating Cancer in People With HIV.
    J Clin Oncol. 2023 Jun 2:JCO2300737. doi: 10.1200/JCO.23.00737.
    PubMed     Abstract available
    
    
    
59. STINCHCOMBE TE
    Flashback Foreword: Afatinib for the Treatment of Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023;41:2867-2868.
    PubMed    
    
    
    May 2023
60. PASSARO A, Janne PA, Peters S
    Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
    J Clin Oncol. 2023 May 24:JCO2300013. doi: 10.1200/JCO.23.00013.
    PubMed     Abstract available
    
    
    
61. SHEPHERD FA, Dancey J, Ramlau R, Mattson K, et al
    Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy.
    J Clin Oncol. 2023;41:2673-2681.
    PubMed     Abstract available
    
    
    
62. HANNA N, Shepherd FA, Fossella FV, Pereira JR, et al
    Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
    J Clin Oncol. 2023;41:2682-2690.
    PubMed     Abstract available
    
    
    
63. STINCHCOMBE TE
    Flashback Foreword: Docetaxel Versus Best Supportive Care in Non-Small-Cell Lung Cancer and Pemetrexed Versus Docetaxel in Second-Line Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023;41:2671-2672.
    PubMed    
    
    
    
64. TANNOCK IF, Goldstein DA, Ofer J, Gyawali B, et al
    Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?
    J Clin Oncol. 2023;41:2713-2717.
    PubMed    
    
    
    
65. MCARTHUR GA
    Combination Immune Checkpoint Inhibition: Is First Line Best?
    J Clin Oncol. 2023;41:2691-2694.
    PubMed    
    
    
    
66. EL ZARIF T, Nassar AH, Adib E, Fitzgerald BG, et al
    Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
    J Clin Oncol. 2023 May 16:JCO2202459. doi: 10.1200/JCO.22.02459.
    PubMed     Abstract available
    
    
    
67. SCAGLIOTTI GV, Parikh P, von Pawel J, Biesma B, et al
    Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023;41:2458-2466.
    PubMed     Abstract available
    
    
    
68. STINCHCOMBE TE
    Flashback Foreword: Cisplatin/Pemetrexed in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023;41:2455-2456.
    PubMed    
    
    
    
69. 
    JCO Flashback: Cisplatin Plus Gemcitabine Vs. Cisplatin Plus Pemetrexed-A Comparative Analysis (2008).
    J Clin Oncol. 2023;41:2457.
    PubMed    
    
    
    
70. AKINBORO O, Drezner N, Amatya A, Runyan J, et al
    US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 May 4:JCO2202509. doi: 10.1200/JCO.22.02509.
    PubMed     Abstract available
    
    
    
71. JOHNSON DH, Fehrenbacher L, Novotny WF, Herbst RS, et al
    Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023;41:2305-2312.
    PubMed     Abstract available
    
    
    
72. STINCHCOMBE TE
    Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC.
    J Clin Oncol. 2023;41:2303-2304.
    PubMed    
    
    
    April 2023
73. 
    Erratum: Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
    J Clin Oncol. 2023 Apr 27:JCO2300658. doi: 10.1200/JCO.23.00658.
    PubMed    
    
    
    
74. DY GK, Govindan R, Velcheti V, Falchook GS, et al
    Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
    J Clin Oncol. 2023 Apr 25:JCO2202524. doi: 10.1200/JCO.22.02524.
    PubMed     Abstract available
    
    
    
75. TENDLER S, Rudin CM
    Tarlatamab-New Star on the Horizon for Small-Cell Lung Cancer?
    J Clin Oncol. 2023 Apr 25:JCO2300148. doi: 10.1200/JCO.23.00148.
    PubMed    
    
    
    
76. STINCHCOMBE TE
    Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma.
    J Clin Oncol. 2023;41:2123-2124.
    PubMed    
    
    
    
77. SINGH N, Jaiyesimi IA, Ismaila N, Leighl NB, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1.
    J Clin Oncol. 2023 Apr 6:JCO2300282. doi: 10.1200/JCO.23.00282.
    PubMed     Abstract available
    
    
    
78. SINGH N, Jaiyesimi IA, Ismaila N, Leighl NB, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1.
    J Clin Oncol. 2023 Apr 6:JCO2300281. doi: 10.1200/JCO.23.00281.
    PubMed     Abstract available
    
    
    
79. BOUSEMA JE, Dijkgraaf MGW, van der Heijden EHFM, Verhagen AFTM, et al
    Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial.
    J Clin Oncol. 2023 Apr 5:JCO2201728. doi: 10.1200/JCO.22.01728.
    PubMed     Abstract available
    
    
    
80. LIN TA, Das A, McCaw Z, Ludmir EB, et al
    Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma.
    J Clin Oncol. 2023 Apr 4:JCO2300072. doi: 10.1200/JCO.23.00072.
    PubMed    
    
    
    March 2023
81. SANDHYA L, Devi Sreenivasan N, Goenka L, Dubashi B, et al
    Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
    J Clin Oncol. 2023 Mar 28:JCO2201997. doi: 10.1200/JCO.22.01997.
    PubMed     Abstract available
    
    
    
82. DE BRAUD F, Dooms C, Heist RS, Lebbe C, et al
    Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
    J Clin Oncol. 2023 Mar 22:JCO2202018. doi: 10.1200/JCO.22.02018.
    PubMed     Abstract available
    
    
    
83. BURTNESS B
    First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?
    J Clin Oncol. 2023 Mar 6:JCO2202349. doi: 10.1200/JCO.22.02349.
    PubMed    
    
    
    February 2023
84. SANCHEZ-MAGRANER L, Gumuzio J, Miles J, Quimi N, et al
    Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Feb 23:JCO2201748. doi: 10.1200/JCO.22.01748.
    PubMed     Abstract available
    
    
    
85. DEEK MP, Haigentz M, Jabbour SK
    Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same.
    J Clin Oncol. 2023 Feb 23:JCO2202316. doi: 10.1200/JCO.22.02316.
    PubMed     Abstract available
    
    
    
86. GARASSINO MC, Gadgeel S, Speranza G, Felip E, et al
    Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
    J Clin Oncol. 2023 Feb 21:JCO2201989. doi: 10.1200/JCO.22.01989.
    PubMed     Abstract available
    
    
    
87. JAIYESIMI IA, Owen DH, Ismaila N, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3.
    J Clin Oncol. 2023 Feb 21:JCO2202783. doi: 10.1200/JCO.22.02783.
    PubMed     Abstract available
    
    
    
88. JAIYESIMI IA, Owen DH, Ismaila N, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3.
    J Clin Oncol. 2023 Feb 21:JCO2202782. doi: 10.1200/JCO.22.02782.
    PubMed     Abstract available
    
    
    
89. FUKUOKA M, Yano S, Giaccone G, Tamura T, et al
    Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023;41:1162-1171.
    PubMed     Abstract available
    
    
    
90. 
    JCO Flashback: Assessing the Effectivity of Gefitinib in Treating Advanced NSCLC (2003).
    J Clin Oncol. 2023;41:1161.
    PubMed    
    
    
    
91. STINCHCOMBE TE
    Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial.
    J Clin Oncol. 2023;41:1159-1160.
    PubMed    
    
    
    
92. SILVESTRI GA, Jett JR
    The Intersection of Lung Cancer Screening, Radiomics, and Artificial Intelligence: Can One Scan Really Predict the Future Development of Lung Cancer?
    J Clin Oncol. 2023 Feb 3:JCO2202885. doi: 10.1200/JCO.22.02885.
    PubMed    
    
    
    
93. NOVELLO S, Kowalski DM, Luft A, Gumus M, et al
    Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
    J Clin Oncol. 2023 Feb 3:JCO2201990. doi: 10.1200/JCO.22.01990.
    PubMed     Abstract available
    
    
    
94. CULAKOVA E, Mohile SG, Peppone L, Ramsdale E, et al
    Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.
    J Clin Oncol. 2023;41:835-846.
    PubMed     Abstract available
    
    
    
95. GONZALEZ SERRANO A, Laurent M, Barnay T, Martinez-Tapia C, et al
    A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis.
    J Clin Oncol. 2023;41:826-834.
    PubMed     Abstract available
    
    
    
96. WIDDER J
    Progression-Free Survival or Failure of Local Treatment Strategy: End Points for Trials Testing Stereotactic Body Radiotherapy.
    J Clin Oncol. 2023;41:938-939.
    PubMed    
    
    
    
97. SCHULTZ KAP, Harris AK, Nelson AT, Watson D, et al
    Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/DICER1 Registry.
    J Clin Oncol. 2023;41:778-789.
    PubMed     Abstract available
    
    
    
98. BENJAMIN DJ, Nagasaka M
    Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?
    J Clin Oncol. 2023;41:742-744.
    PubMed    
    
    
    January 2023
99. HERBST RS, Wu YL, John T, Grohe C, et al
    Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
    J Clin Oncol. 2023 Jan 31:JCO2202186. doi: 10.1200/JCO.22.02186.
    PubMed     Abstract available
    
    
    
100. PAZ-ARES L, Champiat S, Lai WV, Izumi H, et al
     Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study.
     J Clin Oncol. 2023 Jan 23:101200JCO2202823. doi: 10.1200/JCO.22.02823.
     PubMed     Abstract available
     
     
     
101. HERSHMAN DL, Bansal A, Sullivan SD, Barlow WE, et al
     A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
     J Clin Oncol. 2023;41:590-598.
     PubMed     Abstract available
     
     
     
102. MIKHAEL PG, Wohlwend J, Yala A, Karstens L, et al
     Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.
     J Clin Oncol. 2023 Jan 12:JCO2201345. doi: 10.1200/JCO.22.01345.
     PubMed     Abstract available
     
     
     
103. BOGART J, Wang X, Masters G, Gao J, et al
     High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
     J Clin Oncol. 2023 Jan 9:JCO2201359. doi: 10.1200/JCO.22.01359.
     PubMed     Abstract available
     
     
     
104. LI Z, Lu S
     Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
     J Clin Oncol. 2023 Jan 9:JCO2202278. doi: 10.1200/JCO.22.02278.
     PubMed    
     
     
     December 2022
105. OWEN DH, Singh N, Ismaila N, Blanchard E, et al
     Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
     J Clin Oncol. 2022 Dec 19:JCO2202124. doi: 10.1200/JCO.22.02124.
     PubMed     Abstract available
     
     
     
106. OWEN DH, Singh N, Ismaila N, Blanchard E, et al
     Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.
     J Clin Oncol. 2022 Dec 19:JCO2202121. doi: 10.1200/JCO.22.02121.
     PubMed     Abstract available
     
     
     
107. TIAN R, Wiley B, Liu J, Zong X, et al
     Clonal Hematopoiesis and Risk of Incident Lung Cancer.
     J Clin Oncol. 2022 Dec 8:JCO2200857. doi: 10.1200/JCO.22.00857.
     PubMed     Abstract available
     
     
     
108. WU HX, Pan YQ, He Y, Wang ZX, et al
     Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
     J Clin Oncol. 2022 Dec 6:JCO2201490. doi: 10.1200/JCO.22.01490.
     PubMed     Abstract available
     
     
     November 2022
109. YANG JT, Wijetunga NA, Pentsova E, Wolden S, et al
     Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
     J Clin Oncol. 2022;40:3858-3867.
     PubMed     Abstract available
     
     
     
110. SATTLER M, Salgia R
     Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
     J Clin Oncol. 2022 Nov 3:JCO2202086. doi: 10.1200/JCO.22.02086.
     PubMed    
     
     
     
111. JOHNSON ML, Cho BC, Luft A, Alatorre-Alexander J, et al
     Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
     J Clin Oncol. 2022 Nov 3:JCO2200975. doi: 10.1200/JCO.22.00975.
     PubMed     Abstract available
     
     
     October 2022
112. DE CASTRO G JR, Kudaba I, Wu YL, Lopes G, et al
     Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score >/= 1% in the KEYNOTE-042 Study.
     J Clin Oncol. 2022 Oct 28:JCO2102885. doi: 10.1200/JCO.21.02885.
     PubMed     Abstract available
     
     
     
113. CAMIDGE DR, Barlesi F, Goldman JW, Morgensztern D, et al
     Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Oct 26:JCO2200739. doi: 10.1200/JCO.22.00739.
     PubMed     Abstract available
     
     
     
114. BRAHMER JR, Lee JS, Ciuleanu TE, Caro RB, et al
     Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227.
     J Clin Oncol. 2022 Oct 12:101200JCO2201503. doi: 10.1200/JCO.22.01503.
     PubMed     Abstract available
     
     
     
115. WANG Z, Wu L, Li B, Cheng Y, et al
     Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
     J Clin Oncol. 2022 Oct 7:JCO2200727. doi: 10.1200/JCO.22.00727.
     PubMed     Abstract available
     
     
     September 2022
116. LIN JJ, Gainor JF
     Selective Targeting of RET Fusions in Lung Cancer.
     J Clin Oncol. 2022 Sep 19:JCO2201644. doi: 10.1200/JCO.22.01644.
     PubMed    
     
     
     
117. DRILON A, Subbiah V, Gautschi O, Tomasini P, et al
     Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
     J Clin Oncol. 2022 Sep 19:JCO2200393. doi: 10.1200/JCO.22.00393.
     PubMed     Abstract available
     
     
     
118. ADOTEVI O, Vernerey D, Jacoulet P, Meurisse A, et al
     Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
     J Clin Oncol. 2022 Sep 7:JCO2200096. doi: 10.1200/JCO.22.00096.
     PubMed     Abstract available
     
     
     August 2022
119. YUE D, Xu S, Wang Q, Li X, et al
     Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Aug 26:JCO2200428. doi: 10.1200/JCO.22.00428.
     PubMed     Abstract available
     
     
     
120. MIYAUCHI E, Morita S, Nakamura A, Hosomi Y, et al
     Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
     J Clin Oncol. 2022 Aug 12:JCO2102911. doi: 10.1200/JCO.21.02911.
     PubMed     Abstract available
     
     
     
121. ARBOUR KC, Lito P
     Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.
     J Clin Oncol. 2022;40:2609-2611.
     PubMed    
     
     
     
122. OU SI, Janne PA, Leal TA, Rybkin II, et al
     First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1).
     J Clin Oncol. 2022;40:2530-2538.
     PubMed     Abstract available
     
     
     
123. LIGIBEL JA, Bohlke K, May AM, Clinton SK, et al
     Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.
     J Clin Oncol. 2022;40:2491-2507.
     PubMed     Abstract available
     
     
     July 2022
124. SINGH N, Temin S, Baker S Jr, Blanchard E, et al
     Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
     J Clin Oncol. 2022 Jul 11:JCO2200825. doi: 10.1200/JCO.22.00825.
     PubMed     Abstract available
     
     
     
125. SINGH N, Temin S, Baker S Jr, Blanchard E, et al
     Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
     J Clin Oncol. 2022 Jul 11:JCO2200824. doi: 10.1200/JCO.22.00824.
     PubMed     Abstract available
     
     
     June 2022
126. MACK PC, Hirsch FR, Bunn PA, Minna JD, et al
     Longitudinal COVID-19 Vaccination-Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer.
     J Clin Oncol. 2022 Jun 27:JCO2201136. doi: 10.1200/JCO.22.01136.
     PubMed    
     
     
     
127. VALANPARAMBIL RM, Carlisle J, Linderman SL, Akthar A, et al
     Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
     J Clin Oncol. 2022 Jun 27:JCO2102986. doi: 10.1200/JCO.21.02986.
     PubMed     Abstract available
     
     
     
128. PENNELL NA
     Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jun 20:JCO2200827. doi: 10.1200/JCO.22.00827.
     PubMed    
     
     
     
129. PASSARO A, Attili I, de Marinis F
     Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jun 17:JCO2200873. doi: 10.1200/JCO.22.00873.
     PubMed     Abstract available
     
     
     
130. AGGARWAL C, Gyawali B
     Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?
     J Clin Oncol. 2022 Jun 9:JCO2200903. doi: 10.1200/JCO.22.00903.
     PubMed    
     
     
     
131. PEROL M, Swalduz A
     Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?
     J Clin Oncol. 2022 Jun 9:JCO2200859. doi: 10.1200/JCO.22.00859.
     PubMed    
     
     
     
132. RECKAMP KL, Redman MW, Dragnev KH, Minichiello K, et al
     Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
     J Clin Oncol. 2022 Jun 3:JCO2200912. doi: 10.1200/JCO.22.00912.
     PubMed     Abstract available
     
     
     May 2022
133. SOLOMON BJ, Bauer TM, Ignatius Ou SH, Liu G, et al
     Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
     J Clin Oncol. 2022 May 23:JCO2102278. doi: 10.1200/JCO.21.02278.
     PubMed     Abstract available
     
     
     
134. RIVERA MP, Cupertino P, Henderson LM
     Complementary Approaches to Lung Cancer Detection in High-Risk Populations.
     J Clin Oncol. 2022 May 23:JCO2200494. doi: 10.1200/JCO.22.00494.
     PubMed    
     
     
     
135. LU S, Dong X, Jian H, Chen J, et al
     AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
     J Clin Oncol. 2022 May 17:JCO2102641. doi: 10.1200/JCO.21.02641.
     PubMed     Abstract available
     
     
     
136. PROVENCIO M, Serna-Blasco R, Nadal E, Insa A, et al
     Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
     J Clin Oncol. 2022 May 16:JCO2102660. doi: 10.1200/JCO.21.02660.
     PubMed     Abstract available
     
     
     
137. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
     Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
     J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
     PubMed    
     
     
     April 2022
138. HERBST RS, Majem M, Barlesi F, Carcereny E, et al
     COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Apr 22:JCO2200227. doi: 10.1200/JCO.22.00227.
     PubMed     Abstract available
     
     
     
139. WISNIVESKY JP, Smith CB
     Lung Cancer Disparities Outcomes: The Urgent Need for Narrowing Care Gaps.
     J Clin Oncol. 2022 Apr 15:JCO2200321. doi: 10.1200/JCO.22.00321.
     PubMed    
     
     
     March 2022
140. PARK S, Ock CY, Kim H, Pereira S, et al
     Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Mar 10:JCO2102010. doi: 10.1200/JCO.21.02010.
     PubMed     Abstract available
     
     
     
141. OSAROGIAGBON RU, Liao W, Faris NR, Meadows-Taylor M, et al
     Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort.
     J Clin Oncol. 2022 Mar 8:JCO2102496. doi: 10.1200/JCO.21.02496.
     PubMed     Abstract available
     
     
     
142. PUJOL JL
     Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Mar 3:JCO2200204. doi: 10.1200/JCO.22.00204.
     PubMed    
     
     
     February 2022
143. TSAO AS, Pass HI, Rimner A, Mansfield AS, et al
     New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
     J Clin Oncol. 2022;40:681-692.
     PubMed     Abstract available
     
     
     
144. STINCHCOMBE TE, Bradley JD
     Thoracic Oncology: Current Standard Therapy and Future Developments.
     J Clin Oncol. 2022;40:527-529.
     PubMed    
     
     
     
145. PISTERS K, Kris MG, Gaspar LE, Ismaila N, et al
     Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
     J Clin Oncol. 2022 Feb 15:JCO2200051. doi: 10.1200/JCO.22.00051.
     PubMed     Abstract available
     
     
     
146. CHARLOT M, Stein JN, Damone E, Wood I, et al
     Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery.
     J Clin Oncol. 2022 Feb 14:JCO2101745. doi: 10.1200/JCO.21.01745.
     PubMed     Abstract available
     
     
     
147. PIRES DA SILVA I, Ahmed T, McQuade JL, Nebhan CA, et al
     Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
     J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.
     PubMed     Abstract available
     
     
     
148. SPIGEL DR, Faivre-Finn C, Gray JE, Vicente D, et al
     Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Feb 2:JCO2101308. doi: 10.1200/JCO.21.01308.
     PubMed     Abstract available
     
     
     
149. JACOBSON JO
     Who Is MB and What Does She Want?
     J Clin Oncol. 2022;40:427-429.
     PubMed    
     
     
     January 2022
150. MAZIERES J, Lafitte C, Ricordel C, Greillier L, et al
     Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
     J Clin Oncol. 2022 Jan 24:JCO2101455. doi: 10.1200/JCO.21.01455.
     PubMed     Abstract available
     
     
     
151. COOPER AJ, Gainor JF
     Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges Remain.
     J Clin Oncol. 2022 Jan 24:JCO2102550. doi: 10.1200/JCO.21.02550.
     PubMed    
     
     
     
152. FAHRMANN JF, Marsh T, Irajizad E, Patel N, et al
     Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
     J Clin Oncol. 2022 Jan 7:JCO2101460. doi: 10.1200/JCO.21.01460.
     PubMed     Abstract available
     
     
     
153. DAI W, Feng W, Zhang Y, Wang XS, et al
     Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial.
     J Clin Oncol. 2022 Jan 7:JCO2101344. doi: 10.1200/JCO.21.01344.
     PubMed     Abstract available
     
     
     
154. PASSARO A, Brahmer J, Antonia S, Mok T, et al
     Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
     J Clin Oncol. 2022 Jan 5:JCO2101845. doi: 10.1200/JCO.21.01845.
     PubMed     Abstract available
     
     
     
155. CHAFT JE, Shyr Y, Sepesi B, Forde PM, et al
     Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101589. doi: 10.1200/JCO.21.01589.
     PubMed     Abstract available
     
     
     
156. DONINGTON J, Schumacher L, Yanagawa J
     Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101592. doi: 10.1200/JCO.21.01592.
     PubMed     Abstract available
     
     
     
157. TSUI DCC, Camidge DR, Rusthoven CG
     Managing Central Nervous System Spread of Lung Cancer: The State of the Art.
     J Clin Oncol. 2022 Jan 5:JCO2101715. doi: 10.1200/JCO.21.01715.
     PubMed     Abstract available
     
     
     
158. PELLINI B, Chaudhuri AA
     Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
     J Clin Oncol. 2022 Jan 5:JCO2101929. doi: 10.1200/JCO.21.01929.
     PubMed     Abstract available
     
     
     
159. BOGART JA, Waqar SN, Mix MD
     Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101639. doi: 10.1200/JCO.21.01639.
     PubMed     Abstract available
     
     
     
160. TEMEL JS, Petrillo LA, Greer JA
     Patient-Centered Palliative Care for Patients With Advanced Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101710. doi: 10.1200/JCO.21.01710.
     PubMed     Abstract available
     
     
     
161. HIGGINS KA, Puri S, Gray JE
     Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101707. doi: 10.1200/JCO.21.01707.
     PubMed     Abstract available
     
     
     
162. LEVY A, Mercier O, Le Pechoux C
     Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101774. doi: 10.1200/JCO.21.01774.
     PubMed     Abstract available
     
     
     
163. ZUGAZAGOITIA J, Paz-Ares L
     Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
     J Clin Oncol. 2022 Jan 5:JCO2101881. doi: 10.1200/JCO.21.01881.
     PubMed     Abstract available
     
     
     
164. DALY ME
     Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy.
     J Clin Oncol. 2022 Jan 5:JCO2101611. doi: 10.1200/JCO.21.01611.
     PubMed     Abstract available
     
     
     
165. RECK M, Remon J, Hellmann MD
     First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101497. doi: 10.1200/JCO.21.01497.
     PubMed     Abstract available
     
     
     
166. TAN AC, Tan DSW
     Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
     J Clin Oncol. 2022 Jan 5:JCO2101626. doi: 10.1200/JCO.21.01626.
     PubMed     Abstract available
     
     
     
167. JASPER K, Stiles B, McDonald F, Palma DA, et al
     Practical Management of Oligometastatic Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2022 Jan 5:JCO2101719. doi: 10.1200/JCO.21.01719.
     PubMed     Abstract available
     
     
     December 2021
168. DALY ME, Singh N, Ismaila N, Antonoff MB, et al
     Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
     J Clin Oncol. 2021 Dec 22:JCO2102528. doi: 10.1200/JCO.21.02528.
     PubMed     Abstract available
     
     
     November 2021
169. LE X, Cornelissen R, Garassino M, Clarke JM, et al
     Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
     J Clin Oncol. 2021 Nov 29:JCO2101323. doi: 10.1200/JCO.21.01323.
     PubMed     Abstract available
     
     
     
170. DEVARAKONDA S, Li Y, Martins Rodrigues F, Sankararaman S, et al
     Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
     J Clin Oncol. 2021;39:3747-3758.
     PubMed     Abstract available
     
     
     
171. LIU SY, Zhang JT, Wu YL
     What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2021 Nov 18:JCO2102443. doi: 10.1200/JCO.21.02443.
     PubMed    
     
     
     
172. TADA H, Mitsudomi T, Misumi T, Sugio K, et al
     Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
     J Clin Oncol. 2021 Nov 2:JCO2101729. doi: 10.1200/JCO.21.01729.
     PubMed     Abstract available
     
     
     
173. SOULIERES D, Gelmon KA
     Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
     J Clin Oncol. 2021;39:3427-3429.
     PubMed    
     
     
     October 2021
174. BROWN PD, Parsons MW, Rusthoven CG, Gondi V, et al
     Hippocampal Avoidance Prophylactic Cranial Irradiation: A New Standard of Care?
     J Clin Oncol. 2021;39:3093-3096.
     PubMed    
     
     
     September 2021
175. ELAMIN YY, Robichaux JP, Carter BW, Altan M, et al
     Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
     J Clin Oncol. 2021 Sep 22:JCO2101113. doi: 10.1200/JCO.21.01113.
     PubMed     Abstract available
     
     
     
176. DRILON A, Duruisseaux M, Han JY, Ito M, et al
     Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
     J Clin Oncol. 2021;39:2791-2802.
     PubMed     Abstract available
     
     
     August 2021
177. RAMALINGAM SS, Novello S, Guclu SZ, Bentsion D, et al
     Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
     J Clin Oncol. 2021 Aug 26:JCO2003318. doi: 10.1200/JCO.20.03318.
     PubMed     Abstract available
     
     
     
178. RODRIGUEZ DE DIOS N, Counago F, Murcia-Mejia M, Rico-Oses M, et al
     Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.
     J Clin Oncol. 2021 Aug 11:JCO2100639. doi: 10.1200/JCO.21.00639.
     PubMed     Abstract available
     
     
     
179. PARK K, Haura EB, Leighl NB, Mitchell P, et al
     Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
     J Clin Oncol. 2021 Aug 2:JCO2100662. doi: 10.1200/JCO.21.00662.
     PubMed     Abstract available
     
     
     
180. SHU CA, Cascone T
     What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2021 Aug 2:JCO2101446. doi: 10.1200/JCO.21.01446.
     PubMed    
     
     
     July 2021
181. ROTHSCHILD SI, Zippelius A, Eboulet EI, Savic Prince S, et al
     SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
     J Clin Oncol. 2021 Jul 12:JCO2100276. doi: 10.1200/JCO.21.00276.
     PubMed     Abstract available
     
     
     June 2021
182. REMON J, Hendriks LEL, Besse B
     Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2021 Jun 8:JCO2100760. doi: 10.1200/JCO.21.00760.
     PubMed    
     
     
     
183. PASSIGLIA F, Cinquini M, Bertolaccini L, Del Re M, et al
     Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
     J Clin Oncol. 2021 Jun 2:JCO2002574. doi: 10.1200/JCO.20.02574.
     PubMed     Abstract available
     
     
     May 2021
184. GILLESSEN S, Sauve N, Collette L, Daugaard G, et al
     Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
     J Clin Oncol. 2021;39:1563-1574.
     PubMed     Abstract available
     
     
     April 2021
185. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
     Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50.
     J Clin Oncol. 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174.
     PubMed     Abstract available
     
     
     March 2021
186. WAQAR SN, Govindan R
     Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism.
     J Clin Oncol. 2021;39:697-700.
     PubMed    
     
     
     
187. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
     Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
     J Clin Oncol. 2021;39:713-722.
     PubMed     Abstract available
     
     
     February 2021
188. EWER MS, Tekumalla SH, Walding A, Atuah KN, et al
     Cardiac Safety of Osimertinib: A Review of Data.
     J Clin Oncol. 2021;39:328-337.
     PubMed     Abstract available
     
     
     January 2021
189. GYAWALI B, West HJ
     Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
     J Clin Oncol. 2021;39:175-177.
     PubMed    
     
     
     December 2020
190. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
     Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
     J Clin Oncol. 2020;38:4055-4063.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.